Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.00 -2.58% 75.50 1,819,943 14:36:00
Bid Price Offer Price High Price Low Price Open Price
75.00 76.00 77.50 72.00 77.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.58 -7.73 -3.82 163
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:15 O 75,000 75.00 GBX

Angle (AGL) Latest News

More Angle News
Angle Investors    Angle Takeover Rumours

Angle (AGL) Discussions and Chat

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-03-08 17:33:1375.0075,00056,250.00O
2021-03-08 17:24:4874.5065,00048,425.00O
2021-03-08 17:08:1575.50324,786245,213.43O
2021-03-08 17:00:3274.1615,00011,123.25O
2021-03-08 16:59:4574.015,0003,700.50O
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Angle Daily Update: Angle Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 77.50p.
Angle Plc has a 4 week average price of 67.50p and a 12 week average price of 39.75p.
The 1 year high share price is 96.50p while the 1 year low share price is currently 37.50p.
There are currently 215,448,512 shares in issue and the average daily traded volume is 1,590,008 shares. The market capitalisation of Angle Plc is £162,663,626.56.
purchaseatthetop: jelenko...I posted their job listing yesterday and it is impressive. News going to arrive any day and then the 80p's are left behind. AGL is now my largest shareholding (or was until this morning when MCRO overtook it simply because their share price has risen nearly 20% today....)
pj84: Tomphys a bit late in catching up on your post 5360 re a Nasdaq listing. GWPH is a good case history of what might happen. My shares in GWP as they were then, were about 75p,when the went for a dual listing so the shares were on both the UK market and ADR's were issued on the NASDAQ. The company used there NASDAQ listing to raise significant sums on 3 occasions, if memory serves correct, and whilst normally that would dilute your holding as UK holders weren't included in the fund raises the funds raised kept leading to increased share prices so we still benefitted. GWP then went for a full NASDAQ listing and abandoned the UK listing but as the ADR's were traded on Crest I was able to accept ADR's in exchange of my holding in my HL SIPP but you couldn't in an ISA and I was able to continue to benefit. They are now going through a $7 billion acquisition by JAZZ pharmaceuticals a fully listed NASDAQ company and whilst the $220 per share acquisition price for the ADR's equates to about ($220/12*.71) £13 per old share (a 17 bagger) I am still a bit disappointed as like JAZZ I can still see the future potential and most of the consideration is cash and HL have confirmed that I can't reinvest in JAZZ because their shares aren't traded on Crest. I am going to hold my Angle shares for as long as I can and I definitely think a NASDAQ listing will be positive but I hope it doesn't mean that at some point in the future we can no longer benefit.
maytrees: I added earlier but wonder if the 1.4m trade was a sell from way back when? Always irritating when mms report trades well after the event. I may be wrong of course but the AGL share price has been falling for a few days...
jelenko: I see EXAS in U.S. had earnings out yesterday and this was I remember a benchmark company for Angle's Directors a while back. Anyway, EXAS Annual rev $1.4b, current cash $1.8b Mkt Cap $24b! Remember AGL have numerous opportunities each of which is worth the total annual revenue of Exas. But say only one lands and we are also valued at $24b or £17.2b AGL share price On a like for like basis would be £79 assuming no more shares are issued and that's just one opportunity, multiply that by 4 or even more given what Parsortix can contribute. Sound crazy, well that's just what life on Nazdaq is like the sooner the better I think. Even if we strip out the $1.8b cash We get £73 per share. So plenty financial flexibility going forward.
rafboy: I think the current share price still does not reflect anywhere near the value of AGL. FDA approval should be only a matter of a couple of months away and possibly less. With a projected strong chance of approval, what price then? Potential suitors eyeing AGL up fairly shortly after I suspect as well.
banshee: Gold is expensive stuff, if you mean a lump of solid gold moulded into the shape of an Audi A8 (guestimating the A8 vol at say a very conservative 2000 litres) you would need an AGL share price of £10,000+ with 100,000 shares, I think. No harm in dreaming though ;)
purchaseatthetop: IMO....and yes I am biased, and yes I might be accused of ramping, but I have been wrong before.... IF AGL gets the approval then this share price will be seen as the steal of all steals as AGL will revolutionise the entire oncology industry. You can put two 0's behind the share price. Obviously a lot can go wrong and decision can go against us but the mere chance....
miavoce: I agree millwallfan. I've been in AGL a long long time and over the years have seen the share price response to an RNS like today's, which is just the latest in a long line of confirmations of efficacy, become very muted. Quite often the share price may remain static or even decline on the day such an RNS is issued. When I saw the RNS this morning I wasn't therefore expecting any significant share price movement and today's rise has taken me very much by surprise. IMO there is more behind today's rise than the RNS or simply a continuation of recent momentum. The volumes are too high (some very large trades have been reported after hours) and the share price has simply moved too much. I may be completely wrong but we'll see.....
millwallfan: Jelenko. Not sure I could agree it will at least double ‘whatever̶1; the share price is at close the day before approval is announced. We were at 40p no long ago so very decent rise so far. We could now just consolidate which could mean £1.50 or as anticipation and/or confidence lifts pre announcement we could see upward drift to perhaps £1.25 so double would be £2.50. IF (big if) there was a leak ( fact or fiction) of a positive outcome just before decision release we could see £2 , so double would then take us to £4. Just examples but I think in reality the share price post approval will probably reflect market sentiment of the impact value on fundamentals and opportunities rather than just being a simple fixed multiple of whatever the share price happens to be just pre announcement.I guess some knowledgeable potential volume buyers will have already done calculations of fair value. Just my thoughts whilst we play this waiting game. GLA and may this share realise all our dreams and expectations of both medical value for cancer sufferers and wealth generation for shareholders.
millwallfan: As the FDA decision nears I’m sure we are all hoping for true fireworks but in reality whilst it is obviously a massive and lasting positive surely it will take some time for the impact to be fully reflected in the share price i.e. as the test gets adopted across the major markets worldwide and the actual volume of tests get ramped up significantly. As such I am wondering if the INITIAL rise will only push the price up to circa £1.50 ish. The only scenario where I could foresee £2 plus is an early bid just before or after FDA from a major, or even better if there is more than one suitor leading to a bidding war. We know there is one major seeking exclusivity but I understand that the indications from the BOD is that is not a preferred course of action. Comments please if the above is a measured perception or does the balance of opinion given a positive outcome going to take us into 4 to 6 times current share price territory much earlier ???
Angle share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210309 02:05:09